Tengion Retains Jefferies to Explore Strategic Options for the Company

WINSTON-SALEM, N.C., Sep 22, 2014 (GLOBE NEWSWIRE via COMTEX) Tengion, Inc. (OTCQB:TNGN), a leader in regenerative medicine, today announced that the Company, with the support of its Board of Directors, is exploring all strategic options to maximize the value of its assets and has retained Jefferies LLC as exclusive financial advisor to assist it with reviewing and structuring potential strategic transactions. We believe this decision increases our ability to realize the value of our Organ Regeneration Platform and we remain committed to maximizing value for our stakeholders, commented John L. Miclot, President and Chief Executive Officer of Tengion. The Company does not intend to comment further on this process unless and until a definitive agreement has been reached. About Tengion Tengion, a clinical-stage regenerative medicine company, is focused on developing its Organ Regeneration Platform(TM) to harness the intrinsic regenerative pathways of the body to regenerate a range of nat
http://bit.ly/1v0duup